Increasing use of high dose rate, flattening filter free (FFF), and/or small-sized field beams presents a significant challenge to the medical physics community. In this work, we develop a strategy of using a high spatial resolution and high frame rate amorphous silicon flat panel electronic portal imaging device (EPID) for dosimetric measurements of these challenging cases, as well as for conventional external beam therapy. To convert a series of raw EPID-measured radiation field images into water-based dose distribution, a pixel-to-pixel dose-response function of the EPID specific to the linac is essential. The response function was obtained by using a Monte Carlo simulation of the photon transport in the EPID with a comprehensive calibration. After the raw image was converted into the primary incident photon fluence, the fluence was further convolved into a water-based dose distribution of the dynamic field by using a pregenerated pencil-beam kernel. The EPID-based dosimetric measurement technique was validated using beams with and without flattening filter of all energies available in Varian TrueBeam STx TM . Both regularly and irregularly shaped fields measured using a PTW 729 ion chamber array in plastic water phantom. The technique was also applied to measure the distribution for a total of 23 treatment plans of different energies to evaluate the accuracy of the proposed approach. The EPID measurements of square fields of 4 9 4 cm 2 to 20 9 20 cm 2 , circular fields of 2-15 cm diameters, rectangular fields of various sizes, and irregular MLC fields were in accordance with measurements using a Farmer chamber and/or ion chamber array. The 2D absolute dose maps generated from EPID raw images agreed with ion chamber measurements to within 1.5% for all fields. For the 23 patient cases examined in this work, the average c-index passing rate were found to be 99.2 AE 0.6%, 97.4 AE 2.4%, and 72.6 AE 8.4%, respectively, for criterions of 3 mm/3%, 2 mm/2%, and 1 mm/1%. The high spatial resolution and high frame rate EPID provides an accurate and efficient dosimetric tool for QA of modern radiation therapy. Accurate absolute 2D dose maps can be generated from the system for an independent dosimetric verification of treatment delivery.
| INTRODUCTION
The use of amorphous silicon (aSi) flat panel electronic portal imaging device (EPID) for online and offline dosimetric verification has been sought after over the years by several research groups and industrial companies. [1] [2] [3] [4] [5] [6] For example, the Portal Dosimetry TM from Varian Medical Systems (Palo Alto, CA, USA) has been available for pretreatment QA. 1 In this product, beams are directly applied to the portal imager and time-integrated imaging data are acquired. By comparing the measurement with the calculation using the photon fluence from the treatment plan, a QA decision is made based on a series of criteria, such as the percentage difference, distance to agreement (DTA), and c-index analysis. Because the response of the portal imager is quite different from water, this approach is incapable of providing absolute dosimetric information. Instead, it only gives an indirect comparison of fluence. Mans et al. 2 used the EPID to catch errors in routine clinical IMRT and 17 serious errors were detected among 4227 patients treated. McCurdy et al. 3 investigated the dosimetric properties of an EPID operated in continuous acquisition mode for verification of dynamic and arc IMRT. Woodruff et al. 7 and Liu et al. 8 used the approach for pretreatment verification QA of VMAT. Asuni et al. 9 and Lee et al. 10 used EPID images to reconstruct in vivo 3D dose for Stereotactic Body Radiation Therapy (SBRT) QA. Recently, Nelms et al. 11 and Bailey et al. 12 investigated the use of EPIDose TM (Sun Nuclear Corporation, Melbourne FL, USA) for pretreatment QA. The
EPIDose converts an EPID image to dose in water by convolving with an experimentally determined kernel to account for the difference in dose-deposition kernels of the EPID and water. Because the detailed EPID response was not studied, for each MLC-segmented field, an output correction factor must be calculated from MLC plan data and applied to the measurement, which may be a significant source of inaccuracy. Greer et al. 13 developed an EPID-based dose prediction model by incorporating MLC leaf effects for IMRT applications. The EPID dose kernel was calculated using an experimental method and is only specific to the Pinnacle treatment planning system. Warkentin et al. 14 improved the approach with a convolutionbased calibration procedure, in which the physics response of the EPID was deduced from the combination of a Monte Carlo-simulated dose deposition kernel in the EPID phosphor, and an empirically derived kernel describing optical photon spreading. Nicolini et al. 15 had recently demonstrate the feasibility of using EPID dosimetry for flattening filter free (FFF) photon beams by means of the GLAaS methodology to validate it for pretreatment quality assurance of volumetric modulated arc therapy (VMAT), but EPID calibration data were obtained against ion chamber measurements. While all these studies indicated that the EPID is useful as a dosimetric tool, to the best of our knowledge, a complete and accurate method to convert MV photon beams physics response of the EPID to a water-equivalent dose distribution has yet to be obtained with consideration of the generation and transport of the optical photons in the scintillators. Furthermore, there are little investigation adapting EPID for dosimetry of a high dose rate and small field radiation therapy (RT).
This work is thus devoted to develop a strategy of using a high spatial-resolution and high frame rate a-Si EPID for dosimetric verifi- frames of offset-corrected images has to be acquired. Each EPIDmeasured raw image is corrected by using the following equation
The standard flood-field correction method has the effect of removing some beam profiles from the EPID images, such as "horns"
induced by the flattening filter. A beam profile correction matrix was generated by using the field measurement data from water scan measurement data with open beam. Delivery with different total monitor unit and different dose rate were also tested in a previous study. 16 The results exhibited good MU linearity and the dose rate dependency was found to be less than 1%.
2.B | Conversion of the EPID raw images to incident photon fluence
To determine the incident photon beam fluence, it was necessary to simulate and calibrate the EPID device to establish a relationship between EPID pixel values and radiation dose. Detailed structure (a) (b)
The (a) on-couch stationary and (b) on-head rotational settings for the EPID system.
The dose-glare kernel K dp (x, y) of all available WFF (a) and FFF (b) photon energies for deconvolution of EPID-measured raw images into incident primary photon fluence.
The water-equivalent dose kernel K pb (x, y) of all available WFF (a) and FFF (b) photon energies for the reconstruction of water-based dose distribution from the deconvoluted incident primary fluence.
and composition of the EPID were provided by the manufacturer and were modeled using the GATE (Geant4 Application for Tomographic Emission), a GEANT4-based Monte Carlo simulation platform. 17 The source model of photon energy spectrum used in the MC simulations was based on the energy integration method and was evaluated using treatment planning systems ( With the detail EPID modeled using GATE, a deconvolving kernel K de (x, y) was generated. The incident photon fluence Ψ p (x, y) on EPID can thereafter be reconstructed from the corrected EPID raw image and the K de (x, y) using the flowing equation
2.C | Conversion of the reconstructed incident fluence to water-based relative dose distribution
In practice, a water-based dose distribution is measured using different detectors such as an ion chamber, diode, or film with plastic water phantoms for routine dosimetry measurements and patient-specific for all available photon energies were simulated in the MCNPX and specific number of source photons was selected to ensure an acceptable level of statistical uncertainty (< 1% at 3 cm off pencil beam, < 3% at 10 cm off axis for each simulation). The incident photon fluence map Ψ p (x, y) reconstructed from EPID raw measurement was then convolved with the K pb (x, y) to generate a two-dimensional (2D) ) were also studied. 2D absolute dose maps were generated from EPID images using the proposed technique. The c-analysis was performed between EPID measurement, PTW729 measurement, and TPS calculation.
2.D | System validation via standard fields

| RESULTS AND DISCUSSION
3.A | Monte Carlo simulation of pixel-by-pixel response of the EPID
A deconvolving dose kernel K dp (x, y), accounting for the MV photon dose deposition in EPID screen and the optical photon creation and show the change in K dp (x, y) as a function of distance from the central axis for WFF and FFF beams, respectively.
The MCNPX simulated pencil-beam dose kernels K pb (x, y) converted EPID images to 2D dose distribution in water as described in Sec 2C and the results are shown in (Fig. 3) for all available energies.
3.B | System validation via standard fields
In Fig. 4 , EPID-measured output factors of different field sizes are shown along with that obtained using Farmer chamber. Overall, the output factors of square fields obtained using the two approaches agreed within 0.85%. The average discrepancy was found to be 0.02% AE 0.46% (mean AE standard deviation), 0.24% AE 0.53%, 0.10% AE 0.40%, À0.16% AE 0.56%, and 0.25% AE 0.59% for 6, 10, 15 MV WFF, and 6, 10 MV FFF photon beams, respectively. For all photon energies and for circular fields (2-15 cm diameter), rectangular and irregularly shaped fields, the EPID measured relative output factor or central axis dose output were found to agree with the ion chamber measurements to within 1.5%.
In Fig. 5 , we show the EPID-measured dose profiles of various square 6 MV fields. The data obtained using a PTW729 detector and water tank scan are also plotted for comparison. Overall, the profiles obtained using different approaches agree each other very well. Small discrepancies (< 3%) were observed in the shoulder and trail regions of the profiles, presumably because of the PTW729 ion chamber array has more volume averaging effects and lateral scatter equilibrium problems due to the air cavities of the air filled ion chamber array. Therefore, the PTW729 result may not perfectly agree with the water scan result of a single pinpoint ion chamber and EPID-converted dose profile.
To further validate the 2D accuracy of the EPID measurement against PTW729 ion chamber array measurement, c-index criteria of 3%/3 mm, 2%/2 mm, and 1%/1 mm were calculated for all WFF and FFF beams. The results, as presented in (Table 1 ), showed that greater than 99.4% passing rate for the criteria of 3%/3 mm for all energy modes. For the 2%/2 mm and 1%/2 mm c criterion, greater than 92.3% and 67.9% passing rates were achieved, respectively.
Similar c-index test results were found in measurements of circular fields of 2-15-cm diameter, rectangular fields and irregular fields of all photon energies. 3 mm/3%; 2 mm/2%; 1 mm/1%. For the c-index setting of 3 mm/ 3%, the minimum and maximum passing rates were 97.5% and 100%, respectively.
3.C | Clinical case study
| CONCLUSION S
We have developed an EPID-based dosimetric system based on the use of a Monte Carlo-generated pixel response of the system. The EPID-measured absolute dose distribution and output factors for standard square fields ranging from 4 9 4 to 15 9 15 cm 2 were found to agree well with ion chamber data. The off-axis measurement of the EPID was also found to be consistent with PTW729 and water scan data. For the clinical cases with various field sizes, the agreement between EPID-and PTW729-measured values were found to be better than 2.1%. The success of EPID-based system was also supported by the c index analysis. The proposed EPID dosimetric system addresses an important unmet clinical need for an efficient and reliable dose measurement and verification in modern RT.
ACKNOWLED GMENT
This work is partially supported by NIH (1R01 CA133474 and 1R01 EB016777). 
